| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;102:1503.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events
From the University of Michigan Medical Center (B.P.); Wake Forest University School of Medicine (R.P.B., C.D.F., M.E.M., W.R.); University of Minnesota Hospital/Clinic (D.B.H.); and University of British Columbia (G.B.J.M.).
Correspondence to Bertram Pitt, MD, Department of Internal Medicine, Division of Cardiology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3910 Taubman Center, Ann Arbor, MI 48109-0366.
Background—The results of angiographic studies have suggested that calcium channel–blocking agents may prevent new coronary lesion formation, the progression of minimal lesions, or both.
Methods and Results—The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was a multicenter, randomized, placebo-controlled, double-masked clinical trial designed to test whether amlodipine would slow the progression of early coronary atherosclerosis in 825 patients with angiographically documented coronary artery disease. The primary outcome was the average 36-month angiographic change in mean minimal diameters of segments with a baseline diameter stenosis of 30%. A secondary hypothesis was whether amlodipine would reduce the rate of atherosclerosis in the carotid arteries as assessed with B-mode ultrasonography, which measured intimal-medial thicknesses (IMT). The rates of clinical events were also monitored. The placebo and amlodipine groups had nearly identical average 36-month reductions in the minimal diameter: 0.084 versus 0.095 mm, respectively (P=0.38). In contrast, amlodipine had a significant effect in slowing the 36-month progression of carotid artery atherosclerosis: the placebo group experienced a 0.033-mm increase in IMT, whereas there was a 0.0126-mm decrease in the amlodipine group (P=0.007). There was no treatment difference in the rates of all-cause mortality or major cardiovascular events, although amlodipine use was associated with fewer cases of unstable angina and coronary revascularization.
Conclusions—Amlodipine has no demonstrable effect on angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but is associated with fewer hospitalizations for unstable angina and revascularization.
Key Words: amlodipine • atherosclerosis • angiography • ultrasonics • trials • angina • revascularization
This article has been cited by other articles:
 |
|
 |
|
  M. F. Walter, R. F. Jacob, R. E. Bjork, B. Jeffers, J. Buch, Y. Mizuno, R. P. Mason, and on behalf of the PREVENT Investigators Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease: The PREVENT Study J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1196 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Onder, E. Capoluongo, M. Cesari, P. Lulli, R. Liperoti, B. Giardina, A. Russo, R. Bernabei, and F. Landi Association of Calcium Channel Blocker Use and Pregnancy-Associated Plasma Protein-A Among Older Adults With Hypertension: Results From the ilSIRENTE Study J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2007; 62(11): 1274 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Wang, Y. Li, S. S. Franklin, and M. Safar Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview Hypertension, July 1, 2007; 50(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III, J. S. Raichlen, W. A. Riley, G. W. Evans, M. K. Palmer, D. H. O'Leary, D. E. Grobbee, M. L. Bots, and for the METEOR Study Group Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis: The METEOR Trial JAMA, March 28, 2007; 297(12): 1344 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Wang, J. A. Staessen, Y. Li, L. M. Van Bortel, T. Nawrot, R. Fagard, F. H. Messerli, and M. Safar Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials Stroke, July 1, 2006; 37(7): 1933 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Raggi, A. Taylor, Z. Fayad, D. O'Leary, S. Nissen, D. Rader, and L. J. Shaw Atherosclerotic Plaque Imaging: Contemporary Role in Preventive Cardiology Arch Intern Med, November 14, 2005; 165(20): 2345 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-J. Touboul, J. Labreuche, E. Vicaut, P. Amarenco, and on behalf of the GENIC Investigators Carotid Intima-Media Thickness, Plaques, and Framingham Risk Score as Independent Determinants of Stroke Risk Stroke, August 1, 2005; 36(8): 1741 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Blood Pressure Lowering Treatment Trialists' Colla Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials Arch Intern Med, June 27, 2005; 165(12): 1410 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shinoda, Y. Yui, K. Kodama, A. Hirayama, H. Nonogi, K. Haze, T. Sumiyoshi, S. Hosoda, C. Kawai, and for the Japan Multicenter Investigation for Cardio Quantitative Coronary Angiogram Analysis: Nifedipine Retard Versus Angiotensin-Converting Enzyme Inhibitors (JMIC-B Side Arm Study) Hypertension, June 1, 2005; 45(6): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Kahn, K. Boesze-Battaglia, D. W. Stepp, A. Petrov, Y. Huang, R. P. Mason, and T. N. Tulenko Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H591 - H600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J C Spratt and E Camenzind Plaque stabilisation by systemic and local drug administration Heart, December 1, 2004; 90(12): 1392 - 1394. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Walter, R. F. Jacob, B. Jeffers, M. M. Ghadanfar, G. M. Preston, J. Buch, and R. P. Mason Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Nissen, E. M. Tuzcu, P. Libby, P. D. Thompson, M. Ghali, D. Garza, L. Berman, H. Shi, E. Buebendorf, E. J. Topol, et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2217 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. J. Mancini, B. Dahlof, and J. Diez Surrogate Markers for Cardiovascular Disease: Structural Markers Circulation, June 29, 2004; 109(25_suppl_1): IV-22 - IV-30. [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Aihara, H. Azuma, N. Takamori, Y. Kanagawa, M. Akaike, M. Fujimura, T. Yoshida, S. Hashizume, M. Kato, H. Yamaguchi, et al. Heparin Cofactor II Is a Novel Protective Factor Against Carotid Atherosclerosis in Elderly Individuals Circulation, June 8, 2004; 109(22): 2761 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers Blood Pressure and Stroke: An Overview of Published Reviews Stroke, April 1, 2004; 35(4): 1024 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Candido, T. J. Allen, M. Lassila, Z. Cao, V. Thallas, M. E. Cooper, and K. A. Jandeleit-Dahm Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis Circulation, March 30, 2004; 109(12): 1536 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers Blood Pressure and Stroke: An Overview of Published Reviews Stroke, March 18, 2004; 01.STR.0000126208.14181.D. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers Blood Pressure and Stroke: An Overview of Published Reviews Stroke, March 1, 2004; 35(3): 776 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Poredos Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis Vascular Medicine, February 1, 2004; 9(1): 46 - 54. [Abstract] [PDF]
|
|
|
|
|
|
C. Kataoka, K. Egashira, M. Ishibashi, S. Inoue, W. Ni, K.-i. Hiasa, S. Kitamoto, M. Usui, and A. Takeshita Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H768 - H774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.P. Mason, P. Marche, and T.H. Hintze Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2155 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Bots, G. W. Evans, W. A. Riley, and D. E. Grobbee Carotid Intima-Media Thickness Measurements in Intervention Studies: Design Options, Progression Rates, and Sample Size Considerations: A Point of View Stroke, December 1, 2003; 34(12): 2985 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tabrizchi Amlodipine and endothelial nitric oxide synthase activity Cardiovasc Res, October 1, 2003; 59(4): 807 - 809. [Full Text] [PDF]
|
|
|
|
|
|
H. Lenasi, K. Kohlstedt, B. Fichtlscherer, A. Mulsch, R. Busse, and I. Fleming Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495 Cardiovasc Res, October 1, 2003; 59(4): 844 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yu, I. Morita, K. Shimokado, T. Iwai, and M. Yoshida Amlodipine Modulates THP-1 Cell Adhesion to Vascular Endothelium via Inhibition of Protein Kinase C Signal Transduction Hypertension, September 1, 2003; 42(3): 329 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Dens, W J Desmet, P Coussement, I K De Scheerder, K Kostopoulos, P Kerdsinchai, C Supanantaroek, and J H Piessens Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study Heart, August 1, 2003; 89(8): 887 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Mason and R. F. Jacob Membrane Microdomains and Vascular Biology: Emerging Role in Atherogenesis Circulation, May 6, 2003; 107(17): 2270 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
J. A Staessen, J.-G. Wang, and W. H Birkenhager Outcome beyond blood pressure control? Eur. Heart J., March 2, 2003; 24(6): 504 - 514. [Full Text] [PDF]
|
|
|
|
|
|
V. S. Monroe, R. A. Kerensky, E. Rivera, K. M. Smith, and C. J. Pepine Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 23S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ENCORE Investigators* Effect of Nifedipine and Cerivastatin on Coronary Endothelial Function in Patients With Coronary Artery Disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) Circulation, January 28, 2003; 107(3): 422 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Messerli, W. B. White, and J. A. Staessen If only cardiologists did properly measure blood pressure: Blood pressure recordings in daily practice and clinical trials J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2201 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Law, H. C. Watt, and N. J. Wald The Underlying Risk of Death After Myocardial Infarction in the Absence of Treatment Arch Intern Med, November 25, 2002; 162(21): 2405 - 2410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zanchetti, M. G. Bond, M. Hennig, A. Neiss, G. Mancia, C. Dal Palu, L. Hansson, B. Magnani, K.-H. Rahn, J. L. Reid, et al. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial Circulation, November 5, 2002; 106(19): 2422 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Hong, W. Riley, J. Rhyne, G. Friel, and M. Miller Lack of Association between Increased Carotid Intima-Media Thickening and Decreased HDL-Cholesterol in a Family with a Novel ABCA1 Variant, G2265T Clin. Chem., November 1, 2002; 48(11): 2066 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Wang and J. A. Staessen Conventional Therapy and Newer Drug Classes for Cardiovascular Protection in Hypertension J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S208 - 215. [Abstract] [Full Text]
|
|
|
|
|
|
R. Nosadini and G. Tonolo Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus: The Role of Calcium Channel Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S216 - 223. [Abstract] [Full Text]
|
|
|
|
|
|
R. P. Byington, C. D. Furberg, D. M. Herrington, J. A. Herd, D. Hunninghake, M. Lowery, W. Riley, T. Craven, L. Chaput, C. C. Ireland, et al. Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1692 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Deanfield, J.-M. Detry, P. Sellier, P. R. Lichtlen, E. Thaulow, J. Bultas, C. Brennan, S. T. Young, B. Beckerman, and CAPE II Trial Investigators Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial J. Am. Coll. Cardiol., September 4, 2002; 40(5): 917 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Achenbach, D. Ropers, K. Pohle, A. Leber, C. Thilo, A. Knez, T. Menendez, R. Maeffert, M. Kusus, M. Regenfus, et al. Influence of Lipid-Lowering Therapy on the Progression of Coronary Artery Calcification: A Prospective Evaluation Circulation, August 27, 2002; 106(9): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Lange, D. W. Bowden, C. D. Langefeld, L. E. Wagenknecht, J. J. Carr, S. S. Rich, W. A. Riley, and B. I. Freedman Heritability of Carotid Artery Intima-Medial Thickness in Type 2 Diabetes Stroke, July 1, 2002; 33(7): 1876 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.A. Riley Carotid intima-media thickness: risk assessment and scanning protocol Eur. Heart J., June 2, 2002; 23(12): 916 - 918. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Klein Treatment patterns in stable angina: objectives and reality Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O8 - O11. [Abstract] [PDF]
|
|
|
|
|
|
F. H. Messerli, B. Pitt, R. P. Byington, C. D. Furberg, D. B. Hunninghake, G.B. J. Mancini, M. E. Miller, and W. Riley Confusing Press Releases and the PREVENT Study Response Circulation, October 30, 2001; 104 (18): e95 - e95. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Barth, A. Iglesias del Sol, D. E. Grobbee, J. C.M. Witteman, and M. L. Bots IMT for the Elderly? Stroke, October 1, 2001; 32(10): 2443 - 2445. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Goldstein, B. Pitt, R. P. Byington, C. D. Furberg, M. E. Miller, W. Riley, D. B. Hunninghake, and G.B. J. Mancini Does Amlodipine Increase Cancer Incidence? Circulation, July 10, 2001; 104 (2): e5 - e5. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Lonn, S. Yusuf, V. Dzavik, C. I. Doris, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, W. A. Riley, and K. K. Teo Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) Circulation, February 20, 2001; 103(7): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1967 - 1971. [Abstract] [Full Text] [PDF]
|
|